Clinical Trial Search

Primary: Number of Participants With Symptomatic or Asymptomatic Intracranial Hemorrhage (ICH) Within 36 Hours From Start of Treatment With DS-1040b in Acute Ischemic Stroke…

Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants

Primary: Mean Change From Baseline to Day 85 in the Distance Walked During the 6 Minute Walk Test (MWT) Following Treatment With SUN11031 in Participants Having Cachexia…

Primary: Reported Change in Seizures Frequency From Baseline at 13 Weeks — 4.4; 189.5 seizures/two weeks

Primary: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus at Day 0 — 0.101; 0.100; 0.102; 0.101 international units per milliliter

Primary: Weight Gain Per Week of Observation — 0.39; 0.33 kg/wk

Primary: Patient Pain Perception — 32.6; 25 millimeters on a visual analogue scale

Primary: AMG 986 Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast) — 80,000; 64,500…

Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants

Primary: Progression-free Survival — 4.9 months

Primary: Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline — 2; 4; 1; 4 Participants

Primary: Number of Patients With Treatment-emergent Adverse Events (TEAEs) — 15; 2; 10; 2 Participants

Primary: Gait Speed — 121.27; 124.89 cm/s — p=0.003

Primary: Maximum Tolerated Dose (MTD) of Efavirenz — 1200 mg

Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…